Identifying biomarkers and surrogates of tumors (cancer biometrics): Correlation with immunotherapies and immune cells

Cancer Immunology, Immunotherapy

Volumn 53, Issue 3, 2004, Pages 256-261

  Lotze, Michael T ^a   Rees, Robert C ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Biomarkers; Cancer biometrics; Cancer proteomics; Genome instability

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 2; OLIGONUCLEOTIDE; TUMOR MARKER;

ARTIFICIAL NEURAL NETWORK; BIOMETRY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CORRELATION ANALYSIS; DENDRITIC CELL; DNA MICROARRAY; EPITHELIUM TUMOR; GENOME ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; IMAGE CYTOMETRY; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; MELANOMA; METASTASIS; ONCOGENE; OVARY CANCER; PATHOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SPECTROSCOPY; T LYMPHOCYTE; TIME OF FLIGHT MASS SPECTROMETRY; TUMOR CELL; VALIDATION PROCESS;

CLINICAL TRIALS; GENOMIC INSTABILITY; HUMANS; IMMUNOTHERAPY; NEOPLASM CIRCULATING CELLS; NEOPLASMS; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 1542297652     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0487-3     Document Type: Review

References (68)

1. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860-867
2. O'Byrne KJ, Dalgleish AG (2001) Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 85(4):473-483
3. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539-545
4. Petricoin E, Ardekani A, Hitt B, Levine P, Fusaro V, Steinberg S et al (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577
5. Issaq H, Veenstra T, Conrads T, Felschow D (2002) The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 292:587-592
6. Adam B, Qu Y, Davis J, Ward M, Clements M, Cazares L et al (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62:3609-3614
7. Wright G Jr, Cazares L, Leung S-M, Nasim S, Adam B-L, Yip T-T et al (1999) ProteinChip surface enhanced laser desorption/ionization mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostate Dis 2:264-276
8. Vlahou A, Schellhammer P, Mentrinos S, Patel K, Kondylis F, Gong L et al (2001) Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Path 158:1491-1502
9. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362(9382):433-439
10. Mian S, Ball G, Hornbuckle J, Holding F, Carmichael J, Ellis I, Ali S, Li G, McArdle S, Creaser C, Rees R (2003) A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions. Proteomics 3(9):1725-1737
11. Li J, Zhang Z, Rosenzweig J, Wang Y, Chan D (2003) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48:1296-1304
12. Poon T, Yip T-T, Chan A, Yip C, Yip V, Mok T et al (2003) Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49:752-760
13. Ball G, Mian S, Holding F, Allibone RO, Lowe J, Ali S, Li G, McCardle S, Ellis IO, Creaser C, Rees RC (2002) An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 18(3):395-404
14. Lotze MT (2003) The critical need for cancer biometrics: quantitative, reproducible measures of cancer to define response to therapy. Curr Opin Investig Drugs 4(6):649-651
15. Diamandis EP (2003) Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 95:489-490
16. Petricoin E III, Ornstein D, Paweletz C, Ardekani A, Hackett P, Hitt B et al (2002) Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94:1576-1578
17. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ (2003) Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56(3):171-182
18. Kapur R (2002) Fluorescence imaging and engineered biosensors: functional and activity-based sensing using high content screening. Ann NY Acad Sci 961:170-175
19. Ghosh R, Chen Y, DeBiasio R, DeBiasio RL, Conway BMLDK (2003) Cell-based, high-content screen for receptor internalization, recycling and intracellular trafficking. Bio-Techniques 29:170-175
20. Taylor D, Woo EGA (2001) Real-time molecular and cellular analysis: the new frontier of drug discovery. Curr Concepts Oncol 12:75-81
21. Giuliano K, Taylor D (1998) Fluorescent-protein biosensors: new tools for drug discovery. Trends Biotechnol 16:135-140
22. Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA et al (2002) Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 3:research0035.1-0035.17
23. Wang E, Miller L, Ohnmacht G, Mocellin S, Perez-Diez A, Petersen D et al (2002) Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62:3581-3586
24. Mocellin S, Ohnmacht G, Wang E, Marincola FM (2001) Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int J Cancer 93:236-242
25. Wang E, Marincola FM (2001) cDNA arrays and the enigma of melanoma immune responsiveness. Cancer J 7:16-24
26. Wang E, Marincola FM (2000) A natural history of melanoma: serial gene expression analysis. Immunol Today 21:619-623
27. Wang E, Miller L, Ohnmacht G, Liu E, Marincola F (2000) High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 18:457-459
28. Whitney A, Diehn M, Popper S, Alizadeh A, Boldrick J, Relman D et al (2002) Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A 100:1896-1901
29. Perez OD, Nolan GP (2002) Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol 20:155-162
30. Kuss I, Rabinowich H, Gooding W, Edwards R, Whiteside TL (2002) Expression of zeta in T cells prior to interleukin-2 therapy as a predictor of response and survival in patients with ovarian carcinoma. Cancer Biother Radiopharm 17(6):631-640
31. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Higashi H, Iwashige H, Aridome K, Hokita S, Aikou T (2002) CD3-zeta chain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 94(5):1437-1442
32. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL (2001) The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 91(11):2136-147
33. Dworacki G, Meidenbauer N, Kuss I, Hoffmann TK, Gooding W, Lotze M, Whiteside TL (2001) Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 7[Suppl 3]:947s-957s
34. Tsao H, Nadiminti U, Sober A, Bigby M (2001) A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol 137:325-330
35. Brownbridge G, Gold J, Edward M, MacKie R (2001) Evaluation of the use of the tyrosinase-specific and melan A/MART-1-specific reverse transcriptase-coupled polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol 144:279-287
36. Raja S, Mascarenhas BA, Herrera L, Rao U, Gupta D, Edington H, Kirkwood J, Hughes SJ, Godfrey TE (2003) Molecular staging of sentinel lymph nodes in patients with melanoma by quantitative RT-PCR. Proc Am Assoc Cancer Res 44:1013
37. McArdle SE, Ali SA, Li G, Mian S, Rees RC (2003) Phenotypic and functional differences of dendritic cells generated under different in vitro conditions.Methods Mol Med 81:359-375
38. Lotze MT, Jaffe R (2001) Section IV. Dendritic cells and disease - cancer. In: Dendritic cells, 2nd edn. Lotze MT, Thomson A (eds) Academic Press, London
39. Schwaab T, Weiss JE, Schned AR, Barth RJ (2001) Dendritic cell infiltration in colon cancer. J Immunother 24(2):130-137
40. Suzuki A, Masuda A, Nagata H, Kameoka S, Kikawada Y, Yamakawa M, Kasajima T (2002) Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J Pathol 196(1):37-43
41. Schwaab T, Schned AR, Heaney JA, Cole BF, Atzpodien J, Wittke F, Ernstoff MS (1999) In vivo description of dendritic cells in human renal cell carcinoma. J Urol 162(2):567-573
42. Chen S, Akbar SM, Tanimoto K, Ninomiya T, Iuchi H, Michitaka K, Horiike N, Onji M (2000) Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett 148(1):49-57
43. Takahashi A, Kono K, Itakura J, Amemiya H, Feng Tang R, Iizuka H, Fujii H, Matsumoto Y (2002) Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology 62(2):121-127
44. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, Gon G, Toyoda M, Tanigawa N (2003) Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 104(1):92-97
45. Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN (1998) Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 4(3):585-593
46. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, Banchereau J (1999) In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190(10):1417-1426
47. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6(5):1755-1766
48. Vuckovic S, Fearnley DB, Gunningham S, Spearing RL, Patton WN, Hart DN (1999) Dendritic cells in chronic myelomonocytic leukaemia. Br J Haematol 105(4):974-985
49. Tsuge T, Yamakawa M, Tsukamoto M (2000) Infiltrating dendritic/ Langerhans cells in primary breast cancer. Breast Cancer Res Treat 59(2):141-152
50. Inoue K, Furihata M, Ohtsuki Y, Fujita Y (1993) Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis. Virchows Arch A Pathol Anat Histopathol 422(5):351-355
51. Eisenthal A, Polyvkin N, Bramante-Schreiber L, Misonznik F, Hassner A, Lifschitz-Mercer B (2001) Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum Pathol 32(8):803-807
52. Ambe K, Mori M, Enjoji M (1989) S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 63(3):496-503
53. Dallal RM, Christakos P, Lee K, Egawa S, Son YI, Lotze MT (2002) Paucity of dendritic cells in pancreatic cancer. Surgery 131(2):135-138
54. Suzuki A, Masuda A, Nagata H, Kameoka S, Kikawada Y, Yamakawa M, Kasajima T (2002) Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J Pathol 196(1):37-43
55. Furihata M, Ohtsuki Y, Ido E, Iwata J, Sonobe H, Araki K, Ogoshi S, Ohmori K (1992) HLA-DR antigen- and S-100 protein-positive dendritic cells in esophageal squamous cell carcinoma-their distribution in relation to prognosis. Virchows Arch B Cell Pathol Incl Mol Pathol 61(6):409-414
56. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6(5):1755-1766
57. Mihm MC Jr, Clemente CG, Cascinelli N (1996) Tumor infiltrating lymphocytes in lymph node melanoma metatases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74:43-47
58. Hakansson A, Gustafsson B, Krysander L, Hakansson L (1996) Tumor-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 74:670-676
59. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203-213
60. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M (1997) The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79(12):2320-2328
61. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodriguez-Perales S, Diaz-Uriarte R, Dominguez O, Hardisson D, Andujar M, Prat J, Matias-Guiu X, Cigudosa JC, Palacios J (2003) Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 63(18):5697-5702
62. Han JH, Kang Y, Shin HC, Kim HS, Kang YM, Kim YB, Oh SY (2003) Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. Arch Pathol Lab Med 127(10):1330-1334
63. Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA, Ahrendt SA (2003) Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res 9(11):4165-4171
64. Basik M, Mousses S, Trent J (2003) Integration of genomic technologies for accelerated cancer drug development. Biotechniques 35(3):580
65. Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, Scherf U, Reinhold WC, Waltham M, Charboneau L, Young L, Bussey KJ, Kim S, Lababidi S, Lee JK, Pittaluga S, Scudiero DA, Sausville EA, Munson PJ, Petricoin EF 3rd, Liotta LA, Hewitt SM, Raffeld M, Weinstein JN (2003) Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 63(17):5243-5250
66. Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C, Viens P, Mozziconacci MJ, Houlgatte R, Birnbaum D, Jacquemier J (2002) Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 161(4):1223-1233
67. Anderson D, Li W, Payan DNW (2003) A new algorithm for the evaluation of shotgun peptide sequencing in proteomics: support vector machine classification of peptide MS/MS spectra and SEQUEST scores. J Proteome Res 2:137
68. Van Gestel T, Suykens J, Lanckriet G, Lambrechts A, De Moor B, Vandewalle J (2002) Bayesian framework for least-squares support vector machine classifiers, Gaussian processes, and kernel Fisher discriminant analysis. Neural Comput 14:1115-1117